Phase IIb trial of edratide (hCDR1) in patients with systemic lupus erythematosus

Trial Profile

Phase IIb trial of edratide (hCDR1) in patients with systemic lupus erythematosus

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Edratide (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2016 According to a XTL Biopharmaceuticals media release, the trial design has been completed for this trial.
    • 25 Jan 2016 According to XTL Biopharmaceuticals media release, the Company has received written guidance from the U.S. Food and Drug Administration (FDA) in response to a pre-investigational new drug (IND) meeting package regarding its upcoming IND filing for its drug candidate.Based on the FDA's response, XTL plans to file its IND.
    • 25 Jan 2016 According to XTL Biopharmaceuticals media release, company plans to review with its Clinical Advisory Board as it finalizes the study protocol including doses and study duration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top